The output is a list of genetic alterations that are then usually annotated with drugs matched 1:1 to a single identified variant. Identifying the best treatment can be challenging for oncologists when traditional molecular profiling reports present either a list of potential drugs or none at all.

NGS lists genetic alterations and drug recommendations based on a patient's genetic profile. However, this approach often leaves oncologists with a long list of possible drugs (or no drugs at all), resulting in confusion and a lack of actionable insights. Genomate offers a revolutionary solution beyond just providing data on a list of variants and drugs. Genomate analyzes all of a tumor's genetic alterations in combination using data from thousands of pieces of evidence and a decade of research. It generates a personalized report ranking the best drugs to treat the patient's unique tumor profile, providing the patient with the best shot toward a positive outcome.

Let's explore how Genomate outperforms traditional NGS testing reports in providing actionable insights and optimizing cancer treatment.